ELOB

Across TCGA pan-cancer cohorts, ELOB mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ELOB data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ELOB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ELOB expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

CCRCC, PDAC, and OV are the cancer types where ELOB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.580	0.905	<.001	66	view →
PDAC	DFS	Median	All	0.742	0.851	.002	22	view →
OV	DFS	Tertile	All	0.671	0.965	.042	16	view →
GBM	OS	Quartile	All	0.527	1.000	.001	4	view →
UCEC	OS	Quartile	III,IV	1.000	0.265	.040	4	view →
HNSC	OS	Median	IV	0.580	0.826	.011	3	view →
LUAD	OS	Median	III,IV	0.684	0.280	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ELOB–CCRCC (DFS)

Open the CCRCC breakdown →